drugset / Trial / NCT01355562
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-02
- Completion
- 2012-02
Outcome
Outcome not reported
Stopped: “Primary Investigator is no longer employed at LLU as of 02/29/12.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |